Detalles de la búsqueda
1.
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
JAMA
; 331(3): 201-211, 2024 01 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38227033
2.
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Lancet Oncol
; 23(2): 220-233, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35038432
3.
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 23(6): 739-747, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35576956
4.
The performance of detecting Mycobacterium tuberculosis complex in lung biopsy tissue by metagenomic next-generation sequencing.
BMC Pulm Med
; 22(1): 288, 2022 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35902819
5.
Ultradeep Lysine Crotonylome Reveals the Crotonylation Enhancement on Both Histones and Nonhistone Proteins by SAHA Treatment.
J Proteome Res
; 16(10): 3664-3671, 2017 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28882038
6.
CD3, CD8, IFN-γ, tumor and stroma inflammatory cells as prognostic indicators for surgically resected SCLC: evidences from a 10-year retrospective study and immunohistochemical analysis.
Clin Exp Med
; 24(1): 99, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38748269
7.
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Cancer Commun (Lond)
; 44(4): 455-468, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38421881
8.
SAHA treatment reveals the link between histone lysine acetylation and proteome in nonsmall cell lung cancer A549 Cells.
J Proteome Res
; 12(9): 4064-73, 2013 Sep 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23909948
9.
Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer.
Cancer Med
; 12(3): 2666-2676, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36052772
10.
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.
Signal Transduct Target Ther
; 8(1): 301, 2023 08 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37574511
11.
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia.
Immunotherapy
; 15(13): 1029-1044, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37465924
12.
Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial.
EClinicalMedicine
; 59: 101952, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37096188
13.
Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial.
Signal Transduct Target Ther
; 8(1): 249, 2023 06 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37385995
14.
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.
Nat Cancer
; 4(6): 860-871, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37322367
15.
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.
J Thorac Oncol
; 18(5): 628-639, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36646210
16.
Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer.
Front Pharmacol
; 13: 944685, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36386178
17.
Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report.
Front Oncol
; 12: 954886, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36052259
18.
Acute Respiratory Distress Syndrome Caused by Occupational Exposure to Waterproofing Spray: A Case Report and Literature Review.
Front Public Health
; 10: 830429, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35284363
19.
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Lancet Respir Med
; 10(11): 1019-1028, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35662408
20.
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study.
J Thorac Oncol
; 17(11): 1297-1305, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35932953